Abstract
Background: In the early 1980s breast preservation was a rarely applied therapeutic modality in the primary treatment of breast cancer in the Federal Republic of Germany. Reports coming from retrospective studies as well as preliminary results from randomized trials made it desirable to introduce breast preservation in the form of a controlled clinical trial.
Study design: In stage pT1 N0 M0 breast cancer, mastectomy as the standard treatment was to be compared with radiotherapy of the remaining breast tissue. The study design originally planned as a randomized trial had to be changed into a prospective observation study due to the low randomization rate. Univariate analysis of prognostic variables was the first step to a valid treatment comparison. Those factors determined as being significant were included together with the treatment effects in a multivariate analysis. A high therapeutic standard was guaranteed by quality control.
Results: 1036 out of 1119 recruited patients are evaluable. After a median follow-up of 48 months the following preliminary results can be reported. With the exception of death without recurrence from breast cancer, the 143 events are evenly distributed among the two treatment groups. Locoregional recurrence of the whole patient population was 5%. Out of all prognostic factors examined only tumor size and grading are significant in regard to recurrent disease. Recurrence-free survival decreased in cases with ‘uncertain’ tumor margins, whereas the width of the margin had no influence on recurrent disease. There was no significant difference in quality of life between the two treatment groups.
Conclusions: The four-year results of this study are in accordance with those of other breast preservation trials: There is no significant difference between the two treatment groups in the occurrence of locoregional failure. Incomplete tumorectomy has a negative influence on recurrence. Quality of life seems more dependent on the acceptance of the therapy by the patient than on the therapeutic modality itself. Breast preservation can also be performed appropriately in smaller institutions if the therapeutic standard is guaranteed by quality control.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amalric RF, Santamaria F, Robert Ret al. Radiation therapy with or without primary limited surgery for operable breast cancer. A 20-year experience at the Marseilles Cancer Institute, Cancer 49: 30, 1982
Calle R, Pilleron JP, Schlienger P, Vilcoq JR. Conservative management of operable breast cancer. 10 years experience at the Foundation Curie. Cancer 42: 2045–2053, 1978
Sarazzin D, Lê MG, Arrigada Ret al. Ten-year-results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 14: 177, 1989
Veronesi U, Saccozzi R, Del Vecchio Met al. Comparing radical mastectomy with quadrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. N Engl J Med 305: 6, 1981
Olschewski M, Schumacher M. Statistical analysis of quality of life data in cancer clinical trials. Statistics in Medicine 9: 749–763, 1990
Sauer R, Schauer A, Rauschecker HF, Schumacher M, Gatzemeier W, Schmoor C, Dunst J, Seegenschmiedt MH, Marx Det al. Therapy of small breast cancer: A prospective study on 1036 patients with specific emphasis on prognostic factors. Int J Radiat Oncol Biol Pub 23: 907–914, 1992
Seegenschmiedt MH, Sauerbrei W, Sauer R, Schumacher M, Schauer A, Rauschecker HFet al. Quality control review for radiotherapy of small breast cancer: Analysis of 708 patients in the GBSG I trial. Strahlentherapie und Onkologie 169: 339–350, 1993
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc B 34: 187–220, 1972
Peto R, Pike MCet al. Design and analysis of clinical trials requiring prolonged observation of each patient. Part I: Br J Cancer 34: 585; Part II: Br J Cancer 35: 1, 1976/1977
Olschewski M, Verres R, Scheurlen H, Rauschecker HF. Evaluation of psychosocial aspects in a breast preservation trial. Rec Res Cancer Res 111: 258–269, 1988
Olschewski M, Rauschecker HF. Assessment of quality of life in the GBSG trial ‘breast preserving treatment in patients with early-stage breast cancer’. The Breast 2: 208, 1993
Fisher B, Margolese Ret al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312: 665–673, 1985
Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS. Geographic variation on the use of breast-conserving treatment for breast cancer. N Engl J Med 326: 17; 1102–1107, 1992
Wolberg WH. Surgical options in 424 patients with primary breast cancer without systemic metastases. Arch Surg 126: 817–820, 1991
Liberati A, Himel HN, Chalmers TC. A quality assessment of randomized controlled trials of primary treatment of breast cancer. J Clin Oncol 4: 942–951, 1986
Veronesi U, Volterrani F, Luini V, Saccozzi R, Del Vecchio Met al. Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer 26: 6, 671–673, 1990
Fisher B, Redmond C, Poisson R, Margolese R, Wolmark Net al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320: 13, 822–828, 1989
van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G,et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 Trial. Monographs, Journal of the National Cancer Institute 11: 15–18, 1992
Straus K, Lichter A, Lippmann M, Danforth D, Swain S, Cowan K, de Moss Eet al. Results of the National Cancer Institute Early Breast Cancer Trial. Monographs, Journal of the National Cancer Institute 11: 27–32, 1992
McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82: 1006–1015, 1990
Sigurdsson H, Baldetorp B, Borg Å, Dalberg M, Fernö M, Killander D, Olsson H. Indicators of prognosis in node-negative breast cancer. N Engl J Med 322: 15, 1045–1053, 1990
Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients: A review. Journal of the National Cancer Institute 85: 15, 1206–1219, 1993
Bloom HJS, Richardson WW. Histological grading and prognosis in breast cancer. Brit J Cancer 11: 339–377, 1957
Schumacher M, Schmoor C, Sauerbrei W, Schauer A, Ummenhofer Let al. The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Research and Treatment 25: 235–245, 1993
Kiebert GM, De Haes JCJM, Van de Velde CJH. The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: A review. Journal of Clinical Oncology 9: 1059–1070, 1991
Fallowfied LJ, Hall A, Maguire GP, Baum M. Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. BMJ 301:575–580, 1990
Author information
Authors and Affiliations
Consortia
Additional information
This study was sponsored by the Ministry of Research and Technology (BMFT) of the Federal Republic of Germany.
Rights and permissions
About this article
Cite this article
The German Breast Cancer Study Group (GBSG)., Rauschecker, H.F., Sauer, R. et al. Therapy of small breast cancer - four-year results of a prospective non-randomized study. Breast Cancer Res Tr 34, 1–13 (1995). https://doi.org/10.1007/BF00666486
Issue Date:
DOI: https://doi.org/10.1007/BF00666486